Immunomic Therapeutics is focusing on the possible application of LAMP technology in oncology after signing a $ 300 million deal with Astellas Pharma for the application of its
platform for allergic diseases.
Professor Moffatt said: «The genes we identified represent new potential drug
targets for allergic diseases as well as biomarkers that may predict which patients will respond to existing expensive therapies.»
Years later, when the children were around 8 years old, they evaluated them for things like doctor - diagnosed asthma, wheezing, hay fever, eczema, atopy (also known as the genetic tendency to develop allergic diseases), serum total IgE (a common way to
test for allergic disease), and lung function.